Discovery and validation of a molecular signature for the noninvasive diagnosis of human renal allograft fibrosis

Transplantation

Volumn 93, Issue 11, 2012, Pages 1136-1146

  Anglicheau, Dany ^a,b   Muthukumar, Thangamani ^a,c   Hummel, Aurélie ^b,c   Ding, Ruchuang ^c   Sharma, Vijay K ^c   Dadhania, Darshana ^c   Seshan, Surya V ^c   Schwartz, Joseph E ^a,c,d   Suthanthiran, Manikkam ^a,c  

^a JES and MS   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

Fibrosis; Gene expression; Kidney transplantation

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CADHERIN; CALVASCULIN; CD103 ANTIGEN; GRANZYME B; MESSENGER RNA; PERFORIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA 18S; SCATTER FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN;

18S RIBOSOMAL RNA GENE; ADULT; ALPHA SMOOTH MUSCLE ACTIN GENE; ARTICLE; CD103 GENE; COLLAGEN 1A1 GENE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; E CADHERIN GENE; FEMALE; FIBROBLAST SPECIFIC PROTEIN 1 GENE; FIBRONECTIN 1 GENE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC MODEL; GRANZYME B GENE; HEPATOCYTE GROWTH FACTOR GENE; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY FIBROSIS; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MOLECULAR DIAGNOSIS; NKCC2 GENE; NON INVASIVE MEASUREMENT; PERFORIN GENE; PLASMINOGEN ACTIVATOR INHIBITOR 1 GENE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TISSUE INHIBITOR OF METALLOPROTEINASE 1 GENE; TRANSFORMING GROWTH FACTOR BETA1 GENE; URINALYSIS; VALIDATION PROCESS; VIMENTIN GENE;

ADULT; BIOLOGICAL MARKERS; BIOPSY; CADHERINS; CROSS-SECTIONAL STUDIES; FEMALE; FIBROSIS; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; RNA, MESSENGER; RNA, RIBOSOMAL, 18S; ROC CURVE; SENSITIVITY AND SPECIFICITY; SODIUM-POTASSIUM-CHLORIDE SYMPORTERS; VIMENTIN;

EID: 84862298374     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31824ef181     Document Type: Article

References (50)

1. Arias M, Serón D, Moreso F, et al. Renal allograft damage: existing challenges. Transplantation 2011; 91: 4.
2. Yilmaz S, Isik I, Afrouzian M, et al. Evaluating the accuracy of functional biomarkers for detecting histological changes in chronic allograft nephropathy. Transpl Int 2007; 20: 608.
3. Huraib S, Goldberg H, Katz A, et al. Percutaneous needle biopsy of the transplanted kidney: technique and complications. Am J Kidney Dis 1989; 14: 13.
4. Beckingham IJ, Nicholson ML, Bell PR. Analysis of factors associated with complications following renal transplant needle core biopsy. Br J Urol 1994; 73: 13.
5. Benfield MR, Herrin J, Feld L, et al. Safety of kidney biopsy in pediatric transplantation: a report of the Controlled Clinical Trials in Pediatric Transplantation Trial of Induction Therapy Study Group. Transplantation 1999; 67: 544.
6. Sorof JM, Vartanian RK, Olson JL, et al. Histopathological concordance of paired renal allograft biopsy cores: effect on the diagnosis and management of acute rejection. Transplantation 1995; 60: 1215.
7. Colvin RB, Cohen AH, Saiontz C, et al. Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. J Am Soc Nephrol 1997; 8: 1930.
8. Nicholson ML, Wheatley TJ, Doughman TM, et al. A prospective randomized trial of three different sizes of core-cutting needle for renal transplant biopsy. Kidney Int 2000; 58: 390.
9. Joh K, Morozumi K, Kitamura H. Symposium: evaluating the reproducibility of pathological diagnosis using the 1997 Banff classification update. Clin Transplant 2006; 20(suppl 15): 53.
10. Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344: 947.
11. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 2342.
12. Anglicheau D, Suthanthiran M. Noninvasive prediction of organ graft rejection and outcome using gene expression patterns. Transplantation 2008; 86: 192.
13. Maluf DG, Mas VR, Archer KJ, et al. Molecular pathways involved in loss of kidney graft function with tubular atrophy and interstitial fibrosis. Mol Med 2008; 14: 276.
14. Strutz F. Pathogenesis of tubulointerstitial fibrosis in chronic allograft dysfunction. Clin Transplant 2009; 23(suppl 21): 26.
15. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010; 6: 643.
16. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010; 21: 1819.
17. Park W, Griffin M, Grande JP, et al. Molecular evidence of injury and inflammation in normal and fibrotic renal allografts one year posttransplant. Transplantation 2007; 83: 1466.
18. Scherer A, Gwinner W, Mengel M, et al. Transcriptome changes in renal allograft protocol biopsies at 3 months precede the onset of interstitial fibrosis/tubular atrophy (IF/TA) at 6 months. Nephrol Dial Transplant 2009; 24: 2567.
19. Seron D, Moreso F. Protocol biopsies in renal transplantation: prognostic value of structural monitoring. Kidney Int 2007; 72: 690.
20. Park WD, Griffin MD, Cornell LD, et al. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010; 21: 1987.
21. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.
22. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65.
23. Ivaska J, Pallari HM, Nevo J, et al. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res 2007; 313: 2050.
24. Nakatsuji S, Yamate J, Sakuma S. Relationship between vimentin expressing renal tubules and interstitial fibrosis in chronic progressive nephropathy in aged rats. Virchows Arch 1998; 433: 359.
25. Bielesz B, Sirin Y, Si H, et al. Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J Clin Invest 2010; 120: 4040.
26. Hertig A, Anglicheau D, Verine J, et al. Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol 2008; 19: 1584.
27. Zeisberg M, Soubasakos MA, Kalluri R. Animal models of renal fibrosis. Methods Mol Med 2005; 117: 261.
28. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199.
29. Sharma VK, Bologa RM, Xu GP, et al. Intragraft TGF-beta 1 mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996; 49: 1297.
30. Hotchkiss H, Chu TT, Hancock WW, et al. Differential expression of profibrotic and growth factors in chronic allograft nephropathy. Transplantation 2006; 81: 342.
31. Mas V, Maluf D, Archer K, et al. Establishing the molecular pathways involved in chronic allograft nephropathy for testing new noninvasive diagnostic markers. Transplantation 2007; 83: 448.
32. Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170: 1807.
33. Kriz W, Kaissling B, Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest 2011; 121: 468.
34. Koesters R, Kaissling B, Lehir M, et al. Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am J Pathol 2010; 177: 632.
35. Yang J, Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 2002; 13: 96.
36. Yang J, Dai C, Liu Y. Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol 2002; 13: 2464.
37. Yang J, Dai C, Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J Am Soc Nephrol 2005; 16: 68.
38. Liu Y, Tolbert EM, Lin L, et al. Up-regulation of hepatocyte growth factor receptor: an amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure. Kidney Int 1999; 55: 442.
39. Liu Y. Hepatocyte growth factor and the kidney. Curr Opin Nephrol Hypertens 2002; 11: 23.
40. Liu Y, Rajur K, Tolbert E, et al. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int 2000; 58: 2028.
41. Mizuno S, Matsumoto K, Kurosawa T, et al. Reciprocal balance of hepatocyte growth factor and transforming growth factor-beta 1 in renal fibrosis in mice. Kidney Int 2000; 57: 937.
42. Mizuno S, Matsumoto K, Nakamura T. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int 2001; 59: 1304.
43. Lohr JW, Lee TP, Farooqui M, et al. Increased levels of serum hepatocyte growth factor in patients with end-stage renal disease. J Med 2000; 31: 131.
44. Mizuno S, Matsumoto K, Nakamura T. HGF as a renotrophic and anti-fibrotic regulator in chronic renal disease. Front Biosci 2008; 13: 7072.
45. Xu GP, Sharma VK, Li B, et al. Intragraft expression of IL-10 messenger RNA: a novel correlate of renal allograft rejection. Kidney Int 1995; 48: 1504.
46. Suthanthiran M, Ding R, Sharma V, et al. Urinary cell messenger RNA expression signatures anticipate acute cellular rejection: a report from CTOT-04. Am J Transplant 2011; 11(suppl 2): 29.
47. Anglicheau D, Sharma VK, Ding R, et al. MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci USA 2009; 106: 5330.
48. Hastie TJ, Tibshirani RJ. Generalized additive models (with discussion). Stat Sci 1986; 1: 297.
49. Hastie TJ, Tibshirani RJ. Generalized Additive Models. New York, NY: Chapman & Hall; 1990.
50. Hosmer DW Jr, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons; 1989.